SST

Somatostatin

Score: 0.527 Price: $0.53 Low Druggability Status: active Wiki: SST

🧠 Neurodegeneration

HYPOTHESES

5

PAPERS

0

KG EDGES

21

DEBATES

1

3D Protein Structure

🧬 SST — PDB 3ODU Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.41

Clinical Stage

Approved

Target Class

Ligand

Safety

0.70

Druggability Analysis

Drug Development0.90

Structural Tractability0.70

Target Class0.50

Safety Profile0.70

Key Metrics

PDB Structures:

3

Known Drugs:

2

Approved:

2

In Clinical Trials:

0

Drug Pipeline (2 compounds)

2 Approved

Druggability Rationale: The somatostatin (SST) receptor system demonstrates moderate druggability for neurodegeneration, with existing approved compounds like octreotide and lanreotide suggesting potential therapeutic utility. Structural data from three PDB entries and AlphaFold predictions provide molecular insights, while the moderate druggability score and existing receptor agonist/antagonist strategies indicate potential for targeted neurological interventions. The presence of active clinical trials exploring neuroprotective mechanisms further supports the target's translational potential.

Mechanism: Somatostatin is a peptide neurotransmitter that modulates neuronal signaling by inhibiting hormone release and neuronal excitability, with emerging evidence suggesting its potential neuroprotective role in neurodegenerative processes through regulation of inflammatory responses and synaptic plasticity. In neurodegeneration contexts, SST receptors may serve as modulators of neuroinflammatory cascades and potentially mitigate progressive neuronal damage through receptor-mediated signaling mechanisms.

Drug Pipeline (2 compounds)

2 Approved

Known Drugs:

Octreotide (approved) — Neuroendocrine tumors

Lanreotide (approved) — Neuroendocrine tumors

Structural Data:

PDB (3) ✓AlphaFold ✓Cryo-EM ✓

UniProt: P61278

🧬 3D Protein Structure

🧬 SST — PDB 3ODU Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is assessed at the receptor level. Ligand traps may cross-react with related growth factors sharing receptor subunits.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

0

Completed

5

Total Enrollment

640

By Phase

PHASE2: 1 · PHASE3: 2 · PHASE4: 2 · Unknown: 3

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis Completed

PHASE4 NCT00108355 n=29

Ascites, Cirrhosis

Interventions: Albumin, Intravenous Saline Infusion (Albumin pla, Midodrine

Sponsor: US Department of Veterans Affairs | Started: 2003-12

Effect of Octreotide on the Colonic Motility in Pediatric Patients Completed

PHASE4 NCT01917773 n=13

Colonic Motility Index, Constipation

Interventions: Octreotide, Bisacodyl

Sponsor: Indiana University | Started: 2013-08

Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia Completed

Unknown NCT05171751 n=50

Congenital Hyperinsulinaemic Hypoglycaem, Octreotide Adverse Reaction

Interventions: Octreotide Injection

Sponsor: Beijing Children's Hospital | Started: 2021-11-01

Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers Completed

Unknown NCT00222092 n=300

Post-ERCP Acute Pancreatitis

Sponsor: University of Ioannina | Started: 2005-09

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly T Completed

Unknown NCT00234520 n=225

Acromegaly

Sponsor: Ipsen | Started: 2003-05

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcin Terminated

PHASE3 NCT00092287 n=4

Malignant Carcinoid Syndrome

Interventions: lanreotide Autogel (somatostatin analogu, Sandostatin long acting release (LAR) De

Sponsor: Ipsen | Started: 2004-07

Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study Terminated

PHASE3 NCT02354768 n=19

High Output Stoma

Interventions: Effects of lanreotide with current anti-, Effects of current anti-diarrheal treatm

Sponsor: University Hospital, Strasbourg, France | Started: 2015-10-22

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn

PHASE2 NCT00227773

Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma

Interventions: octreotide acetate, vatalanib, anti-cytokine therapy

Sponsor: Eastern Cooperative Oncology Group

Linked Hypotheses (10)

Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal 0.948

Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to prevent tau propagat0.922

Closed-loop focused ultrasound targeting EC-II SST interneurons to restore gamma gating and block ta0.900

Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and restore perforant-pat0.896

Gamma entrainment therapy to restore hippocampal-cortical synchrony0.851

Optogenetic restoration of hippocampal gamma oscillations via selective SST interneuron activation t0.845

Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST interneurons to restore h0.827

Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling for tau clearance0.827

Closed-loop transcranial alternating current stimulation to restore hippocampal-prefrontal gamma syn0.785

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophagy fl0.784

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

co discussed (1)

expressed in (3)

SST→GABAergic interneuronsSST→ventral tegmental areaSST→medial paralemniscal nucleus

inhibits (5)

MMP9→SSTSST→MMP3SST→MMP9SST→GHRHSST→growth hormone release

involved in (2)

SST→social defeat stressSST→neuropeptide signaling

participates in (1)

SST→GABAergic interneuron networks

references (4)

Olfactory Mucosa, Blood and Urine for Identification of Early Neurodegeneration (NCT06846658)→SSTUPenn Observational Research Repository (NCT04715399)→SSTNav1.1 Sodium Channel→SSTNeprilysin (NEP / CD10 / MME)→SST

regulates (1)

SST→gamma_oscillation

studied in (1)

SST→neuroscience

targets (1)

h-bdbd2120→SST

therapeutic target (1)

Debate History (1)

Should SST (Somatostatin) be prioritized as a therapeutic target for neurodegene2026-04-22